Actively Recruiting
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Led by BeOne Medicines · Updated on 2026-05-14
392
Participants Needed
29
Research Sites
201 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human (FIH) clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of BGB-B2033 administered as monotherapy and in combination with tislelizumab, with or without bevacizumab. The study will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC), alpha-fetoprotein (AFP)-producing gastric cancer (GC), extragonadal yolk sac tumors/non-dysgerminomas, or glypican-3 (GPC3)-positive squamous non-small cell lung cancer (NSCLC).
CONDITIONS
Official Title
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have unresectable, locally advanced, or metastatic hepatocellular carcinoma (BCLC Stage C or Stage B not suitable for curative treatment)
- Participants with alpha-fetoprotein-producing gastric cancer confirmed by blood level or tumor testing
- Participants with histologically confirmed extragonadal yolk sac tumors or non-dysgerminomas with no curative options
- Participants with glypican-3-positive squamous non-small cell lung cancer with prior checkpoint inhibitor treatment
- At least one evaluable lesion for dose escalation and one measurable lesion for safety expansion
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Adequate organ function as defined in the study protocol
- Willingness to provide tumor tissue samples as required
You will not qualify if you...
- Prior treatment targeting glypican-3 (GPC3) or T-cell costimulatory receptor 4-1BB (CD137)
- Active leptomeningeal disease or untreated/uncontrolled brain metastases
- Active autoimmune disease or history of autoimmune disease with risk of relapse
- Any malignancy diagnosed within 2 years before study drug except study cancer or locally recurring malignancy treated with curative intent
- Need for systemic corticosteroids over 10 mg/day prednisone (or equivalent) or other immunosuppressive therapy within 14 days before first study drug dose
- Certain lung, heart, bleeding conditions, or active infections as defined by protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 29 locations
1
City of Hope Phoenix Cancer Center
Goodyear, Arizona, United States, 85338
Actively Recruiting
2
City of Hope National Medical Center
Duarte, California, United States, 91010-3012
Actively Recruiting
3
City of Hope Chicago Cancer Center
Zion, Illinois, United States, 60099
Actively Recruiting
4
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York, United States, 10065-6800
Actively Recruiting
5
Upmc Hillman Cancer Center(Univ of Pittsburgh)
Pittsburgh, Pennsylvania, United States, 15232-1309
Actively Recruiting
6
Scri Oncology Partners
Nashville, Tennessee, United States, 37203-1503
Actively Recruiting
7
Anhui Provincial Hospital
Hefei, Anhui, China, 230000
Actively Recruiting
8
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350025
Actively Recruiting
9
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510515
Actively Recruiting
10
Guangxi Medical University Cancer Hospital Wuxiang Branch
Nanning, Guangxi, China, 530201
Actively Recruiting
11
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China, 150000
Actively Recruiting
12
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430022
Actively Recruiting
13
Hunan Cancer Hospital
Changsha, Hunan, China, 410013
Actively Recruiting
14
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China, 221000
Actively Recruiting
15
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China, 330006
Actively Recruiting
16
The Second Affiliated Hospital of Nanchang Universityhongjiaozhou Branch
Nanchang, Jiangxi, China, 330038
Actively Recruiting
17
Sichuan Cancer Hospital and Institute
Chengdu, Sichuan, China, 610041
Actively Recruiting
18
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003
Actively Recruiting
19
Lishui Central Hospital
Lishui, Zhejiang, China, 323000
Actively Recruiting
20
Hopital Beaujon
Clichy, France, 92110
Actively Recruiting
21
Kindai University Hospital
Sakai, Osaka, Japan, 590-0197
Actively Recruiting
22
Auckland City Hospital
Auckland, New Zealand, 1023
Actively Recruiting
23
Hospital Oncologico
Rio Piedras, Puerto Rico, 00935
Actively Recruiting
24
Cha Bundang Medical Center, Cha University
BundangGu SeongnamSi, Gyeonggi-do, South Korea, 13496
Actively Recruiting
25
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea, 13620
Actively Recruiting
26
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, South Korea, 06351
Actively Recruiting
27
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, South Korea, 03722
Actively Recruiting
28
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, South Korea, 03080
Actively Recruiting
29
Asan Medical Center
SongpaGu, Seoul Teugbyeolsi, South Korea, 05505
Actively Recruiting
Research Team
S
Study Director
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here